Key facts
- GramEye’s last known valuation is $18.9M (Nov 2025).
- It has raised $6.6M; the latest was Grant ($2.7M) in Nov 2025.
- Notable investors include SMBC Venture Capital, Microsoft for Startups, Japan External Trade Organization, DEEPCORE, Beyond Next Ventures — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for GramEye
- ·The full record, as it builds
Funding rounds
No funding rounds for GramEye are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About GramEye
Developer of medical devices designed to automate Gram staining along with deep learning and robotics. The company develops a system that automates, speeds up, and digitizes the Gram staining process using unique technology, enabling doctors to properly prescribe antibiotics in medical settings around the world.
- Sector
- Healthcare
- HQ
- Ibaraki, Japan
- Founded
- 2020
- Employees
- 20
- Website
- grameye.com/
- Ownership
- Privately Held (backing)
GramEye doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GramEye shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GramEye in its N-PORT filings yet. We sweep new filings monthly.